<DOC>
	<DOCNO>NCT01188174</DOCNO>
	<brief_summary>The present trial establish prospective sequential Allogeneic Stem Cell Transplantation ( allo-SCT ) treatment combine salvage chemotherapy Reduced Intensity Conditioning ( RIC ) primary treatment failure Acute Myeloid Leukemia ( AML ) , future innovative strategy compare .</brief_summary>
	<brief_title>Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation Acute Myeloid Leukemia Primary Treatment Failure</brief_title>
	<detailed_description>Primary Endpoint : To improve 2 year overall survival patient primary treatment failure * Secondary Endpoints : - Feasibility early transplantation within multicenter trial - Leukemia-free survival ( LFS ) 2 year transplantation - Leukemia Response rate day +30 , +90 6 month - Cumulative incidence relapse , death leukemia , non-relapse mortality ( NRM ) - Incidence severity acute chronic Graft-versus-Host disease - Feasibility safety early discontinuation immunosuppressive therapy</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Confirmed diagnosis AML status primary induction failure ( i.e . persistent leukemia 2 course induction chemotherapy persist bone marrow hypoplasia follow induction chemotherapy +/minimal residual disease ) Age : 1855 year Availability HLA identical family donor OR unrelated donor match 10/10 allele ( HLAA , B , C , DRB1 , DQB1 ) maximum 1 allele antigen mismatch OR family donor maximum 1 allele mismatch . Have adequate renal hepatic function indicate follow laboratory value : Serum creatinine ≤1.0 mg/dL ; serum creatinine &gt; 1.0 mg/dL , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73 m² calculate Modification Diet Renal Disease equation Predicted GFR ( ml/min/1.73 m2 ) = 186 x ( Serum Creatinine ) 1.154 x ( age year ) 0.023 x ( 0.742 patient female ) Serum bilirubin ≤1.5 mg/dL × upper limit normal ( ULN ) Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≤2.5 × ULN Alkaline phosphatase ≤2.5 × ULN Documented chloroma Patients AML M3 Documented leukemic infiltration CNS/cerebrospinal fluid Karnofsky performance score &lt; 60 % Acute chronic heart failure HIV infection , chronic viral hepatitis Severe neurological psychiatric disorder Any circumstance preclude use drug use within protocol Prior allogeneic autologous stem cell transplantation &gt; 3 course prior chemotherapy Denied inform consent Pregnancy deny effective contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>AML</keyword>
	<keyword>primary induction failure</keyword>
</DOC>